PREFER, NCT05883956: A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia |
|
|
| Active, not recruiting | 3 | 13 | RoW | Subcutaneous azacitidine, Oral decitabine/cedazuridine | Otsuka Australia Pharmaceutical Pty Ltd | Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference | 01/25 | 05/25 | | |
NCT04256317: A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML |
|
|
| Recruiting | 2/3 | 317 | Canada, US | Azacitidine, Vidaza, ASTX030 (cedazuridine + azacitidine), Cedazuridine | Taiho Oncology, Inc. | Myelodysplastic Syndromes, Chronic Myelocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm | 12/25 | 04/26 | | |
NCT04608110: A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome |
|
|
| Recruiting | 1 | 40 | Japan | ASTX030 | Otsuka Pharmaceutical Co., Ltd. | Myelodysplastic Syndrome (MDS) | 04/25 | 05/25 | | |